Recent Quotes (30 days)

You have no recent quotes
chg | %

Pivot Pharmaceuticals Inc  

(Public, OTCMKTS:PVOTF)   Watch this stock  
Find more results for OTC:NEUKF
-0.050 (-20.00%)
Jun 24 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.07 - 0.23
52 week 0.07 - 1.25
Open 0.07
Vol / Avg. 9,900.00/5,324.00
Mkt cap 14.99M
P/E     -
Div/yield     -
EPS -0.12
Shares 74.92M
Beta -15.15
Inst. own     -

Key stats and ratios

Q4 (Oct '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -17.25% -28634.40%
Return on average equity -33.89% -
CDP Score - -


1275 6th Ave W
+1-604-8057783 (Phone)
+1-604-2250588 (Fax)


Pivot Pharmaceuticals Inc., formerly Neurokine Pharmaceuticals Inc., is a development-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic pharmaceutical products. The Company offers products for women's health and neurological targets. For women's health, the Company's product pipeline includes P-001, which is used for the treatment of dysmenorrhea, lower urinary tract symptoms and kidney stones; P-002, which is used for the treatment of peri-menopausal hot flushes, and P-003, which is used for the prevention and treatment of migraine headaches and the progression from mild cognitive impairment to dementia (Alzheimer's Disease progression). For neurological, the Company offers NK-001, which is used for the treatment of neurocognitive impairment in post-coronary artery bypass graft (CABG or heart bypass) surgery patients, and NK-002, a development-stage drug used for the treatment of Alzheimer's disease.

Officers and directors

Ahmad Doroudian Ph.D. Chairman of the Board
Age: 51
Pravin R. Chaturvedi Ph.D. Chief Executive Officer, Director
Age: 52
Moira Ong Chief Financial Officer
Age: 40
Patrick Frankham Ph.D. Vice President - Business Development, Director
Age: 43
Wolfgang Renz Ph.D Director
Age: 46